We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.31%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.3B
AUM Growth
-$2.36B
Cap. Flow
-$405M
Cap. Flow %
-2.65%
Top 10 Hldgs %
84.69%
Holding
128
New
12
Increased
7
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$36M
2
AKRO
Akero Therapeutics
AKRO
+$34.4M
3
VERU icon
Veru
VERU
+$23.2M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$22.8M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$21.7M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$311M
2
INSM icon
Insmed
INSM
+$51.2M
3
LEGN icon
Legend Biotech
LEGN
+$47.1M
4
KRYS icon
Krystal Biotech
KRYS
+$27.9M
5
PACB icon
Pacific Biosciences
PACB
+$24.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$6.42B 42.04%
46,912,266
– –
INCY icon
2
Incyte
INCY
$25.3B
$2.41B 15.78%
36,154,574
+457
+0% +$33.8K
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$1.57B 10.3%
11,668,897
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$686M 4.49%
41,923,486
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.9B
$646M 4.23%
7,620,494
– –
ASND icon
6
Ascendis Pharma A/S
ASND
$16.5B
$501M 3.28%
4,852,655
– –
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
$254M 1.66%
3,732,502
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.44B
$160M 1.05%
12,710,818
– –
RYTM icon
9
Rhythm Pharmaceuticals
RYTM
$7.33B
$149M 0.97%
6,062,702
+1,937,640
+47% +$36M
KOD icon
10
Kodiak Sciences
KOD
$2.44B
$134M 0.88%
17,310,490
– –
IMCR icon
11
Immunocore
IMCR
$1.68B
$118M 0.77%
2,520,731
+1
+0% +$48
ABCL icon
12
AbCellera Biologics
ABCL
$1.63B
$103M 0.68%
10,450,180
– –
ARGX icon
13
argenx
ARGX
$54.9B
$98.9M 0.65%
280,159
-839,398
-75% -$311M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$98.5M 0.64%
1,409,784
– –
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.4B
$97.4M 0.64%
1,499,213
– –
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
$92.6M 0.61%
1,792,657
– –
TVTX icon
17
Travere Therapeutics
TVTX
$5.12B
$81.3M 0.53%
3,300,009
– –
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$80.6M 0.53%
2,368,378
+2,250,000
+1,901% +$34.4M
TRDA icon
19
Entrada Therapeutics
TRDA
$242M
$76.7M 0.5%
4,865,819
– –
IGMS
20
DELISTED
IGM Biosciences
IGMS
$71.8M 0.47%
3,156,102
– –
REPL icon
21
Replimune Group
REPL
$426M
$67.2M 0.44%
3,893,843
+302,762
+8% +$5.77M
PRLD icon
22
Prelude Therapeutics
PRLD
$359M
$66.9M 0.44%
10,123,824
– –
KYMR icon
23
Kymera Therapeutics
KYMR
$8.61B
$62.7M 0.41%
2,879,825
– –
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$60M 0.39%
969,727
-178,777
-16% -$12.5M
CERS icon
25
Cerus
CERS
$573M
$57.8M 0.38%
16,067,558
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Baker Bros. Advisors held 128 positions worth $15.3B, down 13% from $17.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2022 filing shows 12 new, 7 increased, 17 reduced and 13 closed positions. Its largest new stake was Veru: 160,958 shares worth $18.5M. The largest sale was argenx, an estimated $311M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2022 buy was Veru: 160,958 shares worth $18.5M.
  • Baker Bros. Advisors added most to Rhythm Pharmaceuticals in Q3 2022, an estimated $36M increase.
  • Baker Bros. Advisors's biggest Q3 2022 reduction was argenx, cutting an estimated $311M.
  • Baker Bros. Advisors fully exited Legend Biotech in Q3 2022, selling an estimated $47.1M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.3B portfolio in Q3 2022.
  • Baker Bros. Advisors opened 12 new positions and closed 13 in Q3 2022.
  • Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $15.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.